Novo Nordisk Reports the P-III (STEP Young) Trial Data on Semaglutide to Treat Children Living with Obesity

Shots: Novo Nordisk has reported the P-III (STEP Young) trial data assessing semaglutide (1.7 or 2.4mg based on weight at start of trial; QW, SC) vs PBO in 165 children (6 to <12yrs.) with obesity, both in combination with a reduced-calorie diet & increased physical activity Trial met its 1EP of superior BMI reduction at…

ByRidhi RastogiSeptember 7, 2026

NEWS

Hanmi Pharm Licenses HM17321 to Genentech in ~$2.3B Deal

Shots: Hanmi Pharm has entered into an exclusive licensing agreement with Genentech for the development, manufacturing, & commercialization of HM17321, for obesity & associated conditions such as T2D & CV diseases, globally, excl. South Korea As per the deal, Hanmi will receive ~$190M upfront, with additional development, regulatory & commercial milestones representing the total deal…

ByRidhi RastogiAugust 24, 2026

NEWS

Rhythm Pharmaceuticals’ Imcivree Receives Expanded UK Authorization for Hypothalamic Obesity

Shots: The MHRA has expanded market authorization for Imcivree (setmelanotide) to incl. the treatment of obesity & control of hunger in pts (≥4yrs.) with acquired hypothalamic obesity due to hypothalamic injury or impairment Approval was backed by the global P-II/III (TRANSCEND) trial assessing Imcivree vs PBO in 120 pts with acquired HO, meeting its 1EP with…

ByRidhi RastogiAugust 12, 2026

NEWS

Eli Lilly Reports P-III (TRIUMPH-2 and TRIUMPH-3) Results on Retatrutide for Obesity

Shots: TRIUMPH-2 assessed retatrutide (4, 9, or 12mg, QW) vs PBO in 1152 pts with T2D & obesity/overweight, while TRIUMPH-3 assessed retatrutide (9 or 12mg, QW) in 1949 pts with severe obesity & CV disease; trials used a stepwise dose-escalation approach at Q4W In TRIUMPH-3, 12mg reduced TGs, non-HDL cholesterol, systolic BP, waist circumference, &…

ByRidhi RastogiJuly 24, 2026

NEWS

Novo Nordisk Reports the EC Approval of Wegovy Pill and Wegovy 7.2mg Injection for Weight Management

Shots: The EC approved Wegovy pill (25mg, QD, PO) as an adjunct to lifestyle intervention for weight management in adults with obesity or overweight, with ≥1 weight-related condition; launch expected in H2’26. The EC also approved Wegovy 7.2mg injection in a single-dose pen for obesity Wegovy pill approval was based on the OASIS clinical trial…

ByRidhi RastogiJuly 16, 2026

NEWS

Rani Therapeutics Partners with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Shots: Rani Therapeutics has entered into a research and development collaboration with PegBio to evaluate delivery of multiple obesity & metabolic disease candidates using its proprietary RaniPill platform As per the deal, Rani and PegBio will collaborate on the preclinical development of RaniPill formulations for selected obesity & metabolic disease candidates, aiming to advance the…

ByRidhi RastogiJuly 10, 2026

NEWS

Ascletis Reports the US FDA’s IND Submission for ASC36 and ASC36_35 FDC to Treat Obesity

Shots: The US FDA has received IND applications for ASC36, a QM to Q3M peptide amylin receptor agonist, & ASC36_35 FDC, a QM injection co-formulation of ASC36 + ASC35, for the treatment of obesity In NHP studies, ASC36 SALD showed ~6-fold longer half-life than eloralintide, supporting QM to Q3M SC dosing, while ASC36_35 FDC SALD…

ByRidhi RastogiJuly 6, 2026

NEWS

Eli Lilly’s Retatrutide Delivers Significant Improvements in Weight, A1C, Knee Osteoarthritis Pain, and Obstructive Sleep Apnea (OSA)

Shots: In TRIUMPH-1 trial & nested studies in knee osteoarthritis pain & OSA, retatrutide met all 1EPs at 80wks., with weight loss of 25.9% (9mg) & 28.3% (12mg). At 12mg, 65.3% pts achieved a BMI <30 & 33.3% reached BMI <25, while those with BMI ≥35 lost ~85 lbs through 104wks. It also reduced WOMAC…

ByRidhi RastogiJune 8, 2026

NEWS

Eli Lilly Reports P-III (TRIUMPH-1) Trial Data on Retatrutide for Weight Management

Shots: Trial assessed Lilly’s retatrutide (4, 9 & 12mg) with dose escalation vs PBO in adults with obesity/overweight & ≥1 weight-related comorbidity & without diabetes, meeting 1EP of 19% (4mg), 25.9% (9mg) & 28.3% (12mg) weight loss at 80wks. In 2EPs, retatrutide reduced waist circumference by 16.3cm (4mg), 21.8cm (9mg), & 24.1cm (12mg) vs 3.6cm.…

ByRidhi RastogiMay 21, 2026

NEWS

Vincentage Pharma Reports Topline P-III Trial Data on VCT220 for Weight Management

Shots: Vincentage Pharma has reported topline P-III trial results evaluating VCT220 (120 0r 160mg, QD, PO) vs PBO for 52wks. in 840 Chinese adults with obesity or overweight with ≥1 weight-related comorbidity The trial met its 1EP, showing mean body weight reduction of -12.2% and -12.4% in the 120 & 160mg groups, respectively, vs -1.3% for…

ByRidhi RastogiMay 19, 2026

Novo Nordisk Reports the P-III (STEP Young) Trial Data on Semaglutide to Treat Children Living with Obesity

Hanmi Pharm Licenses HM17321 to Genentech in ~$2.3B Deal

Rhythm Pharmaceuticals’ Imcivree Receives Expanded UK Authorization for Hypothalamic Obesity

Eli Lilly Reports P-III (TRIUMPH-2 and TRIUMPH-3) Results on Retatrutide for Obesity

Novo Nordisk Reports the EC Approval of Wegovy Pill and Wegovy 7.2mg Injection for Weight Management

Rani Therapeutics Partners with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Ascletis Reports the US FDA’s IND Submission for ASC36 and ASC36_35 FDC to Treat Obesity

Eli Lilly’s Retatrutide Delivers Significant Improvements in Weight, A1C, Knee Osteoarthritis Pain, and Obstructive Sleep Apnea (OSA)

Eli Lilly Reports P-III (TRIUMPH-1) Trial Data on Retatrutide for Weight Management

Vincentage Pharma Reports Topline P-III Trial Data on VCT220 for Weight Management

Contact US

FOLLOW US